The company will present findings on Relfydess, Sculptra, and Restylane, along with results from an international survey on aesthetic impacts of medication-driven weight loss.
Galderma will present new data from across its portfolio, including Relfydess, Sculptra, and Restalyne, while also presenting results from a survey on facial changes caused by medication-driven weight loss at the 23rd Aesthetic & Anti-Aging Medicine World Congress in Monaco from March 27-29, 2025.
In total, Galderma will present 11 e-posters, host two symposia, four Masterclass sessions, five Meet-the-Expert sessions, and host an experiential lounge and interactive booth.
“Through our data presentations and expert-led sessions, we reaffirm our commitment to being a leading force in advancing the field of Injectable Aesthetics and equipping healthcare professionals with the innovative solutions they need to fulfill the needs of patients, today and tomorrow,” says Baldo Scassellati Sforzolini, MD, PhD, head of global research and development at Galderma, in a release.
Impact of Medication-driven Weight Loss
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with alterations in facial aesthetic appearance of variable magnitude. In a study investigating facial changes in medication-driven weight loss to date, Galderma surveyed more than 1,300 people across five countries. Findings from this study will be presented, showing 93% of those undergoing weight loss treatment noticed some degree of facial changes during their treatment, and many patients are considering aesthetic treatments to address these, with biostimulators and dermal fillers being the most frequently considered treatments.
The Galderma-sponsored “Medication-Driven Weight Loss: The Algorithms” symposium taking place on Thursday, March 27, as well as a dedicated Masterclass session on Friday, March 28, will explore the effects medication-driven weight loss can have on the face and dive into the ways aesthetic procedures can help restore facial volume and structure.
New Data on Relfydess, Sculptra, and Restylane Shaype
Relfydess
Galderma will present new data from the phase IIIb EXPRESSION and RELAX studies, showing Relfydess achieved rapid onset of action and significant aesthetic improvement in frown lines and crow’s feet.
In the EXPRESSION study, more than 50% of patients reported visible effects as early as day one and, in the RELAX study, effects were sustained through six months, confirming results seen in the READY trial program, and more than a third saw improvement beyond six months in frown lines.
Both studies re-confirmed high patient satisfaction with Relfydess, with 70% of patients in the RELAX study reporting that they preferred treatment with Relfydess versus prior treatments received. Encore data from a post-hoc analysis of the phase III READY program will show that, regardless of baseline wrinkle severity (moderate/severe), subjects treated with Relfydess achieved high rates of improvement in frown lines and crow’s feet, along with improved well-being, and a sustained effect through six months.
Sculptra
Galderma will also present new data on Sculptra (PLLA-SCA), a regenerative biostimulator, reinforcing its formulation, efficacy, and safety. New in vivo comparative data will demonstrate its favorable tissue response and slower, controlled product degradation profile at 52 weeks, as well as lower inflammation, compared to PLLA-GA. The lower inflammation is consistent with Sculptra’s safety profile. Differences in formulation can significantly impact local tissue response and product degradation, affecting potential clinical outcomes such as efficacy and duration.
An expert consensus also confirms Sculptra’s key role in the regenerative aesthetic field, and additional data will show its synergistic effect when paired with Alastin, underscoring its effect across all three skin layers.
Restylane Shaype
Encore data to be presented on Restylane Shaype, powered by Galderma’s proprietary NASHA HD Technology and approved in Canada and most recently in Brazil, will show that it constitutes an innovation in hyaluronic acid fillers as the firmest hyaluronic acid injectable available and displaying the highest G-prime (indicating superior gel strength and firmness) on the market providing a unique bone mimicking effect.
Additional pooled and pivotal phase IV data to be presented will show that Restylane fillers preserve or enhance the natural expressions of 98% of patients while achieving desired aesthetic improvements in attractiveness and youthfulness. This naturalness, combined with high patient satisfaction, represents long-lasting aesthetic improvement.
These e-posters, along with others presented on Dysport and Alastin, will be available.
ID 24863104 © Robert Kneschke | Dreamstime.com
